Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002215 · ClinicalTrials.gov registry record · NA
A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive
A NA study of HIV Infections, sponsored by Triangle Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 1
- Study location
NCT00002215: Completed NA study of HIV Infections, sponsored by Triangle Pharmaceuticals.
NCT00002215 is a NA study of HIV Infections that has completed, run by Triangle Pharmaceuticals. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002215, a NA study of HIV Infections, has completed, sponsored by Triangle Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 1
- Study location
Study Summary
To compare the proportion of patients whose plasma HIV-1 RNA level falls and remains below the limit of quantification by the Roche Amplicor Monitor (400 copies/ml)\[AS PER AMENDMENT 8/4/98: 50 copies/ml\] between weeks 0 and 24. To determine the short-term safety and tolerability of MKC-442 plus nelfinavir (Viracept) plus dual nucleoside analogs. To determine the time to viral failure and time to tolerability failure through Week 48 of therapy.
Conditions Studied
Interventions
- DRUG Nelfinavir mesylate
- DRUG Emivirine
Study Locations (1)
Pennsylvania
- Anderson Clinical Research - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002215
The ClinicalTrials.gov registry entry for NCT00002215 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Triangle Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Nelfinavir mesylate is the first listed.
NCT00002215 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00002215 about?
NCT00002215 is a clinical study titled "A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive". To compare the proportion of patients whose plasma HIV-1 RNA level falls and remains below the limit of quantification by the Roche Amplicor Monitor (400 copies/ml)\[AS PER AMENDMENT 8/4/98: 50 copies/ml\] between weeks 0 and 24. To determine the short-term safety and tolerability of MKC-442 plus ne...
What is the current status of trial NCT00002215?
This trial is currently completed. It is a NA study.
What conditions does trial NCT00002215 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002215?
The interventions under investigation include: Nelfinavir mesylate (DRUG), Emivirine (DRUG).
Who is sponsoring clinical trial NCT00002215?
This trial is sponsored by Triangle Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002215 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.